Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas

Genes Chromosomes and Cancer

Volumn 43, Issue 4, 2005, Pages 414-423

  Martín Subero, José Ignacio ^a   Odero, María Dolores ^b   Hernandez, Roberto ^c   Cigudosa, Juan Cruz ^d   Agirre, Xabier ^e   Saez, Borja ^b   Sanz García, Eduardo ^b   Ardanaz, María T ^c   Novo, Francisco Javier ^b   Gascoyne, Randy D ^f   Calasanz, María José ^b   Siebert, Reiner ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF NAVARRA   (Spain)

^c HOSPITAL TXAGORRITXU   (Spain)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

^e UNIVERSITY OF NAVARRA   (Spain)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN P53; TRANSCRIPTION FACTOR REL;

ADULT; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CYTOGENETICS; DNA REPAIR; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DUPLICATION; GENE FUSION; GENE INACTIVATION; GERMINAL CENTER; HUMAN; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL;

ADULT; DNA-BINDING PROTEINS; GENE AMPLIFICATION; GENES, BCL-2; GENES, MYC; GENES, REL; GERMINAL CENTER; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, B-CELL; MALE; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-6; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 21744448988     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20187     Document Type: Article

References (43)

1. Agirre X, García-Delgado M, Calasanz MJ, Larráyoz MJ, Nova FJ, Vizmanos JL. 2002. Exon concatenation to increase the efficiency of mutation screening by DGGE. Biotechniques 32:1064-1070.
2. Akasaka T, Akasaka H, Ueda C, Yonetani N, Maesako Y, Shimizu A, Yamabe H, Fukuhara S, Uchiyama T, Ohno H. 2000. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. J Clin Oncol 18:510-518.
3. Campbell LJ, Patsouris C, Rayeroux KC, Somana K, Januszewicz EH, Szer J. 2002. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet Cytogenet 139:30-33.
4. Chen W, Butler M, Rao PH, Chaganti SR, Louie DC, Dalla-Favera R, Chaganti RS. 1998a. The t(2;3)(q21;q27) translocation in non-Hodgkin's lymphoma displays BCL6 mutations in the 5′ regulatory region and chromosomal breakpoints distant from the gene. Oncogene 17:1717-1722.
5. Chen W, Iida S, Louie DC, Dalla-Favera R, Chaganti RS. 1998b. Heterologous promoters fused to BCL6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B-cell differentiation. Blood 91:603-607.
6. Cigudosa JC, Parsa NZ, Louie DC, Filippa DA, Jhanwar SC, Johansson B, Mitelman F, Chaganti RS. 1999. Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas. Genes Chromosomes Cancer 25:123-133.
7. Cigudosa JC, Odero MD, Calasanz MJ, Sole F, Salido M, Arranz E, Martinez-Ramirez A, Urioste M, Alvarez S, Cervera JV, MacGrogan D, Sanz MA, Nimer SD, Benitez J. 2003. De novo erythroleukemia chromosome features include multiple rearrangements, with special involvement of chromosomes 11 and 19. Genes Chromosomes Cancer 36:406-412.
8. Difilippantonio MJ, Petersen S, Chen HT, Johnson R, Jasin M. Kanaar R, Ried T, Nussenzweig A. 2002. Evidence for replicative repair of DNA double-strand breaks leading to oncogenic translocation and gene amplification. J Exp Med 196:469-480.
9. Dyer MJ, Lillington DM, Bastard C, Tilly H, Lens D, Heward JM, Stranks G, Morilla R, Monrad S, Guglielmi P, Kluin-Nelemans JC, Hagemeijer A, Young BD, Catovsky D. 1996. Concurrent activation of MYC and BCL2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus. Leukemia 10:1198-1208.
10. Farrugia MM, Duan LJ, Reis MD, Ngan BY, Berinstein NL. 1994. Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-MYC and BCL-2 proto-oncogenes. Blood 83:191-198.
11. Gargallo PM, Cuello MT, Aranguren PN, Larripa IB. 2003. Amplification of the BCR/ABL fusion gene clustered on a masked Philadelphia chromosome in a patient with myeloblastic crisis of chronic myelocytic leukemia. Cancer Genet Cytogenet 143: 140-144.
12. Gladdy RA, Taylor MD, Williams CJ, Grandal I, Karaskova J, Squire JA, Rutka JT, Guidos CJ, Danska JS. 2003. The RAG-1/2 endonuclease causes genomic instability and controls CNS complications of lymphoblastic leukemia in p53/Prkdc-deficient mice. Cancer Cell 3:37-50.
13. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880.
14. Gruszka-Westwood AM, Atkinson S, Summersgill BM, Shipley J, Elnenaei MO, Jain P, Hamoudi RA, Kaeda JS, Wotherspoon AC, Matutes E, Catovsky D. 2002. Unusual case of leukemic mantle cell lymphoma with amplified CCND1/IGH fusion gene. Genes Chromosomes Cancer 33:206-212.
15. Hoglund M, Sehn L, Connors JM, Gascoyne RD, Siebert R, Sall T, Mitelman F, Horsman DE. 2004. Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer 39:195-204.
16. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL, Lynch JC, Armitage JO, Warnke RA, Alizadeh AA, Lossos IS, Levy R, Chan WC. 2002. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 99:2285-2290.
17. Joos S, Menz CK, Wrobel G, Siebert R, Gesk S, Ohl S, Mechtersheimer G, Trümper L, Moller P, Lichter P, Barth TF. 2002. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood 99:1381-1387.
18. Lee JT, Innes DJ Jr, Williams ME. 1989. Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin's lymphoma. J Clin Invest 84: 1454-1459.
19. Lossos IS, Alizadeh AA, Diehn M, Warnke R, Thorstenson Y, Oefner PJ, Brown PO, Botstein D, Levy R. 2002. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA 99:8886-8891.
20. Macpherson N, Lesack D, Klasa R, Horsman D, Connors JM, Barnett M, Gascoyne RD. 1999. Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 17:1558-1567.
21. Marin MC, Hsu B, Stephens LC, Brisbay S. McDonnell TJ. 1995. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo. Exp Cell Res 217:240-247.
22. Martin-Subero JI, Chudoba I, Harder L, Gesk S, Grote W, Novo FJ, Calasanz MJ, Siebert R. 2002a. Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analyses. Am J Pathol 161:413-420.
23. Martin-Subero JI, Gesk S, Harder L, Sonoki T, Tucker PW. Schlegelberger B, Grote W, Novo FJ, Calasanz MJ, Hansmann ML, Dyer MJ, Siebert R. 2002b. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 99:1474-1477.
24. Martin-Subero JI, Harder L, Gesk S, Schlegelberger B, Grote W, Martinez-Climent JA, Dyer MJ, Novo FJ, Calasanz MJ, Siebert R. 2002c. Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. Int J Cancer 98:470-474.
25. Martinez-Climent JA, Alizadeh AA, Segraves R, Blesa D, Rubio-Moscardo F, Albertson DG, Garcia-Conde J, Dyer MJ, Levy R, Pinkel D, Lossos IS. 2003. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 101:3109-3117.
26. McDonnell TJ, Korsmeyer SJ. 1991. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 349:254-256.
27. Metzke-Heidemann S, Harder L, Gesk S, Schoch R, Jenisch S, Grote W, Siebert R, Schlegelberger B. 2001. Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia. Genes Chromosomes Cancer 31:10-14.
28. Mills KD, Ferguson DO, Alt FW. 2003. The role of DNA breaks in genomic instability and tumorigenesis. Immunol Rev 194:77-95.
29. Morel F, Bris MJ, Herry A, Calvez GL, Marion V, Abgrall JF, Berthou C, Braekeleer MD. 2003. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Eur J Haematol 70:235-239.
30. Nathwani BN, Harris NL, Weisenburger D, Isaacson PG, Piris MA, Berger F, Müller-Hermelink HK, Swerdlow SH. 2001. Follicular lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, p 162-167.
31. Phan RT, Dalla-Favera R. 2004. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B-cells. Nature 432: 635-639.
32. Poetsch M, Weber-Matthiesen K, Plendl HJ, Grote W, Schlegelberger B. 1996. Detection of the t(14;18) chromosomal translocation by interphase cytogenetics with yeast-artificial-chromosome probes in follicular lymphoma and nonneoplastic lymphoproliferation. J Clin Oncol 14:963-969.
33. Rodley P, McDonald M, Price B, Fright R, Morris C. 1997. Comparative genomic hybridization teveals previously undescribed amplifications and deletions in the chronic myeloid leukemia-derived K-562 cell line. Genes Chromosomes Cancer 19:36-42.
34. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. 2002. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947.
35. Siebert R, Matthiesen P, Harder S, Zhang Y, Borowski A, Zuhlke-Jenisch R, Metzke S, Joos S, Weber-Matthiesen K, Grote W, Schlegelberger B. 1998. Application of interphase fluorescence in situ Hybridization for the detection of the Burkitt translocation t(8;14)(q24;q32) in B-cell lymphomas. Blood 91:984-990.
36. Strasser A, Harris AW, Bath ML, Cory S. 1990. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331-333.
37. Thangavelu M, Olopade O, Beckman E, Vardiman JW, Larson RA, McKeithan TW, Le Beau MM, Rowley JD. 1990. Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24:q32) or t(8;22)(q24:q11). Genes Chromosomes Cancer 2:147-158.
38. The Non-Hodgkin's Lymphoma Classification Project. 1997. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918.
39. Tilly H, Rossi A, Stamatoullas A, Lenormand B, Bigorgne C, Kunlin A, Monconduit M, Bastard C. 1994. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 84: 1043-1049.
40. van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, Garcia-Sanz R, van Krieken JH, Droese J, Gonzalez D, Bastard C, White HE, Spaargaren M, Gonzalez M, Parreira A, Smith JL, Morgan GJ, Kneba M, Macintyre EA. 2003. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT9S-3936. Leukemia 17:2257-2317.
41. Yano T, Jaffe ES, Longo DL, Raffeld M. 1992. MYC rearrangements in histologically progressed follicular lymphomas. Blood 80:758-767.
42. Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizzera G. 1989. Bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 320:1047-1054.
43. Zhu C, Mills KD, Fetguson DO, Lee C, Manis J, Fleming J, Gao Y, Morton CC, Alt FW. 2002. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translations. Cell 109:811-821.